UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000007664
Receipt No. R000009028
Official scientific title of the study Oral propranolol therapy for infantile hemangiomas
Date of disclosure of the study information 2012/05/01
Last modified on 2017/03/23 (Ver. 8)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Oral propranolol therapy for infantile hemangiomas
Title of the study (Brief title) Oral propranolol therapy for infantile hemangiomas
Region
Japan

Condition
Condition Infantile hemangiomas
Classification by specialty
Plastic surgery
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To assess the efficasy and safety of oral propranolol treatment for infantile hemangiomas
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Change in size of infantile hemangiomas and side effects of propranolol treatment
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Oral propranolol
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
0 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1.Proliferating infantile hemangiomas
2.Informed consent
Key exclusion criteria 1.Patient who has a severe complication without infantile hemangiomas
2.Patient with the past of serious side effect by the propranolol drug
3.Patient with asthma or carbohydrate metabolism
4.Patient who was considered ineligible by the investigators
Target sample size 30

Research contact person
Name of lead principal investigator Ichiro Hashimoto
Organization Tokushima University Hospital
Division name Plastic and Reconstructive Surgery
Address 2-50-1 Kuramoto-tyo, Tokushima, Tokushima
TEL 088-633-7296
Email ichiro.h@tokushima-u.ac.jp

Public contact
Name of contact person Kazuhide Mineda
Organization Tokushima University Hospital
Division name Plastic and Reconstructive Surgery
Address 2-50-1 Kuramoto-tyo, Tokushima, Tokushima
TEL 088-633-7296
Homepage URL
Email mineda.k528@gmail.com

Sponsor
Institute Tokushima University Hospital
Institute
Department

Funding Source
Organization Tokushima University Hospital
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2012 Year 05 Month 01 Day

Progress
Recruitment status Completed
Date of protocol fixation
2012 Year 04 Month 14 Day
Anticipated trial start date
2012 Year 05 Month 01 Day
Last follow-up date
2016 Year 03 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2012 Year 04 Month 04 Day
Last modified on
2017 Year 03 Month 23 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009028